In the BioHarmony Drug Report Database
Fam-trastuzumab deruxtecan-nxki
Enhertu (trastuzumab deruxtecan) is an antibody pharmaceutical. Trastuzumab deruxtecan was first approved as Enhertu on 2019-12-20. It is used to treat breast neoplasms and gastrointestinal neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. It is known to target receptor tyrosine-protein kinase erbB-2.
Trade Name
|
Enhertu |
|---|---|
Common Name
|
trastuzumab deruxtecan |
ChEMBL ID
|
CHEMBL4297844 |
Indication
|
breast neoplasms, gastrointestinal neoplasms |
Drug Class
|
Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives) |
Image (chem structure or protein)
